TransMedics Group, Inc. (TMDX)
↓ Download CSV- Sector Manufacturing
- Incorporated MA
- Fiscal year ends Dec 31
In fiscal 2025, TransMedics Group, Inc. reported revenue of $605.49M, up 37.1% from the prior year. The company was profitable, with a net margin of 31.4% and a gross margin of 59.9%. It held $1.07B in total assets against $595.27M in total liabilities.
Key ratios (FY2025)
59.9%
Gross margin
17.9%
Operating margin
31.4%
Net margin
40.2%
Return on equity
+37.1%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $605.49M | $441.54M | $241.62M | $93.46M | $30.26M | $25.64M | $23.60M | $13.02M | — |
| Cost of Revenue | $242.69M | $179.46M | $87.53M | $28.19M | $9.10M | $9.00M | $9.74M | $7.28M | — |
| Gross Profit | $362.81M | $262.08M | $154.09M | $65.27M | $21.16M | $16.64M | $13.86M | $5.73M | — |
| Operating Income | $108.58M | $37.50M | -$28.73M | -$31.44M | -$39.43M | -$26.38M | -$29.60M | -$20.24M | — |
| Net Income | $190.29M | $35.46M | -$25.03M | -$36.23M | -$44.22M | -$28.75M | -$33.55M | -$23.76M | — |
| EPS (Diluted) | $4.87 | $1.01 | $-0.77 | $-1.23 | $-1.60 | $-1.16 | — | — | — |
| Total Assets | $1.07B | $804.08M | $706.05M | $277.15M | $134.89M | $152.03M | $105.30M | $42.16M | — |
| Total Liabilities | $595.27M | $575.47M | $568.85M | $89.77M | $67.04M | $48.13M | $50.65M | $47.88M | — |
| Shareholders' Equity | $473.10M | $228.60M | $137.20M | $187.38M | $67.85M | $103.89M | $54.65M | -$192.24M | -$168.72M |
| Cash & Equivalents | — | — | $394.81M | $201.18M | $25.58M | $24.58M | $20.09M | $20.24M | — |
| Operating Cash Flow | $192.84M | $48.80M | -$13.03M | -$45.82M | -$28.86M | -$30.27M | -$32.29M | -$25.98M | — |
| Capital Expenditures | $59.25M | $129.74M | $151.85M | $11.91M | $3.52M | $455.0K | $165.0K | $418.0K | — |
| Shares Outstanding | 34.27M | 33.62M | 32.67M | 32.14M | 27.79M | 27.18M | — | — | — |
| Dividends Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — |